Lipidomic Approaches to Study HDL Metabolism in Patients with Central Obesity Diagnosed with Metabolic Syndrome
The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors characterised by central obesity, atherogenic dyslipidaemia, and changes in the circulating lipidome; the underlying mechanisms that lead to this lipid remodelling have only been partially elucidated. This study used an integrated "omics" approach (untargeted whole serum lipidomics, targeted proteomics, and lipoprotein lipidomics) to study lipoprotein remodelling and HDL composition in subjects with central obesity diagnosed with MetS (vs. controls). Compared with healthy subjects, MetS patients showed higher free fatty acids, diglycerides, phosphatidylcholines, and triglycerides, particularly those enriched in products of de novo lipogenesis. On the other hand, the "lysophosphatidylcholines to phosphatidylcholines" and "cholesteryl ester to free cholesterol" ratios were reduced, pointing to a lower activity of lecithin cholesterol acyltransferase (LCAT) in MetS; LCAT activity (directly measured and predicted by lipidomic ratios) was positively correlated with high-density lipoprotein cholesterol (HDL-C) and negatively correlated with body mass index (BMI) and insulin resistance. Moreover, many phosphatidylcholines and sphingomyelins were significantly lower in the HDL of MetS patients and strongly correlated with BMI and clinical metabolic parameters. These results suggest that MetS is associated with an impairment of phospholipid metabolism in HDL, partially led by LCAT, and associated with obesity and underlying insulin resistance. This study proposes a candidate strategy to use integrated "omics" approaches to gain mechanistic insights into lipoprotein remodelling, thus deepening the knowledge regarding the molecular basis of the association between MetS and atherosclerosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 23(2022), 12 vom: 17. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mocciaro, Gabriele [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.06.2022 Date Revised 06.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms23126786 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342643118 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342643118 | ||
| 003 | DE-627 | ||
| 005 | 20240306232123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms23126786 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM342643118 | ||
| 035 | |a (NLM)35743227 | ||
| 035 | |a (PII)6786 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mocciaro, Gabriele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipidomic Approaches to Study HDL Metabolism in Patients with Central Obesity Diagnosed with Metabolic Syndrome |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.06.2022 | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors characterised by central obesity, atherogenic dyslipidaemia, and changes in the circulating lipidome; the underlying mechanisms that lead to this lipid remodelling have only been partially elucidated. This study used an integrated "omics" approach (untargeted whole serum lipidomics, targeted proteomics, and lipoprotein lipidomics) to study lipoprotein remodelling and HDL composition in subjects with central obesity diagnosed with MetS (vs. controls). Compared with healthy subjects, MetS patients showed higher free fatty acids, diglycerides, phosphatidylcholines, and triglycerides, particularly those enriched in products of de novo lipogenesis. On the other hand, the "lysophosphatidylcholines to phosphatidylcholines" and "cholesteryl ester to free cholesterol" ratios were reduced, pointing to a lower activity of lecithin cholesterol acyltransferase (LCAT) in MetS; LCAT activity (directly measured and predicted by lipidomic ratios) was positively correlated with high-density lipoprotein cholesterol (HDL-C) and negatively correlated with body mass index (BMI) and insulin resistance. Moreover, many phosphatidylcholines and sphingomyelins were significantly lower in the HDL of MetS patients and strongly correlated with BMI and clinical metabolic parameters. These results suggest that MetS is associated with an impairment of phospholipid metabolism in HDL, partially led by LCAT, and associated with obesity and underlying insulin resistance. This study proposes a candidate strategy to use integrated "omics" approaches to gain mechanistic insights into lipoprotein remodelling, thus deepening the knowledge regarding the molecular basis of the association between MetS and atherosclerosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a LC-MS | |
| 650 | 4 | |a lecithin cholesterol acyltransferase (LCAT) | |
| 650 | 4 | |a lipidomics | |
| 650 | 4 | |a lipoprotein metabolism | |
| 650 | 4 | |a obesity | |
| 650 | 7 | |a Cholesterol, HDL |2 NLM | |
| 650 | 7 | |a Lipoproteins |2 NLM | |
| 650 | 7 | |a Phosphatidylcholines |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 650 | 7 | |a Phosphatidylcholine-Sterol O-Acyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.3.1.43 |2 NLM | |
| 700 | 1 | |a D'Amore, Simona |e verfasserin |4 aut | |
| 700 | 1 | |a Jenkins, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Kay, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Murgia, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera-Marcos, Luis Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Neun, Stefanie |e verfasserin |4 aut | |
| 700 | 1 | |a Sowton, Alice P |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, Zoe |e verfasserin |4 aut | |
| 700 | 1 | |a Palma-Duran, Susana Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Palasciano, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Reimann, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Suppressa, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Sabbà, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Moschetta, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Koulman, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Griffin, Julian L |e verfasserin |4 aut | |
| 700 | 1 | |a Vacca, Michele |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 23(2022), 12 vom: 17. Juni |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:12 |g day:17 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms23126786 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 12 |b 17 |c 06 | ||